Cargando…

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies

The purpose of this work is to provide an in silico molecular rationale of the role eventually played by currently circulating mutations in the receptor binding domain of the SARS-CoV-2 spike protein (S-RBD(CoV‑2)) in evading the immune surveillance effects elicited by the two Eli Lilly LY-CoV555/ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laurini, Erik, Marson, Domenico, Aulic, Suzana, Fermeglia, Alice, Pricl, Sabrina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511038/ https://www.ncbi.nlm.nih.gov/pubmed/34642465 http://dx.doi.org/10.1038/s41598-021-99827-3

Ejemplares similares

Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence
por: Laurini, Erik, et al.
Publicado: (2021)

Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex
por: Laurini, Erik, et al.
Publicado: (2020)

Unchain My Blood: Lessons Learned from Self-Assembled Dendrimers as Nanoscale Heparin Binders
por: Marson, Domenico, et al.
Publicado: (2019)

Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled in Silico-Experimental Studies. Part II: Self-Assembled siRNA Nanocarriers
por: Laurini, Erik, et al.
Publicado: (2019)

Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled In Silico-Experimental Studies. Part I: Covalent siRNA Nanocarriers
por: Marson, Domenico, et al.
Publicado: (2019)

Perceptions and Misconceptions in Molecular Recognition: Key Factors in Self-Assembling Multivalent (SAMul) Ligands/Polyanions Selectivity
por: Marson, Domenico, et al.
Publicado: (2020)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
por: Bavaro, DF, et al.
Publicado: (2022)

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
por: Pillai, Rajapillai L. I., et al.
Publicado: (2023)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
por: Falcone, Marco, et al.
Publicado: (2021)

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
por: Nathan, Ramesh, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance
por: Guigon, Aurélie, et al.
Publicado: (2022)

Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors
por: Piras, Sandra, et al.
Publicado: (2019)

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
por: Pommeret, F., et al.
Publicado: (2021)

Molecular and functional characterization of a new 3′ end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib
por: Perfetti, Vittorio, et al.
Publicado: (2017)

Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region
por: Vena, Antonio, et al.
Publicado: (2021)

Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis
por: Tai, Yu-Lin, et al.
Publicado: (2023)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study
por: Cicco, Sebastiano, et al.
Publicado: (2023)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
por: Ernest, C. Steven, et al.
Publicado: (2022)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
por: Mazzotta, Valentina, et al.
Publicado: (2022)

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
por: Dougan, Michael, et al.
Publicado: (2021)

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial
por: Chen, Peter, et al.
Publicado: (2022)

Synthesis of Aminoethyl‐Substituted Piperidine Derivatives as σ(1) Receptor Ligands with Antiproliferative Properties
por: Holtschulte, Catharina, et al.
Publicado: (2022)

Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment
por: Ziouziou, Hajer, et al.
Publicado: (2017)

Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment
por: Ziouziou, Hajer, et al.
Publicado: (2018)

Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection
por: Faisal, Muhammad Salman, et al.
Publicado: (2022)

Nanomechanical DNA resonators for sensing and structural analysis of DNA-ligand complexes
por: Stassi, Stefano, et al.
Publicado: (2019)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
por: Focosi, Daniele, et al.
Publicado: (2022)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
por: Wang, Fengze, et al.
Publicado: (2022)

Caution: Chemical Instability of Natural Biomolecules During Routine Analysis
por: Pannequin, Anaïs, et al.
Publicado: (2020)

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rnujruekgjpg4mkrsnt4g4hn2a